AC Immune SA (ACIU)Healthcare | Biotechnology | Lausanne, Switzerland | NasdaqGM
2.65 USD
-0.06
(-2.214%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.65 |
Hot Take ↕ | Aug. 22, 2026, 2:04 a.m. EDT
The immediate catalyst here is the amended collaboration agreement with Eli Lilly, which has successfully halted the bleeding and sparked a sharp price rally, pushing the stock above its 50-day moving average. While the statistical forecasting model whispers a slight downside bias (-4%), its low confidence makes it irrelevant against the tangible momentum generated by the news flow and the aggressive call buying at the $5 strike. However, the long-term outlook remains precarious; despite the recent stabilization, the company has suffered five consecutive years of negative annual returns over the last eight-year window, with a cumulative loss of nearly 74%. The balance sheet is fragile, showing negative free cash flow and negative gross margins, meaning the stock is currently trading on hope and partnership potential rather than intrinsic business value. Until the pipeline delivers definitive clinical proof and cash flow turns positive, this remains a high-risk speculative play rather than a solid investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.040671 |
| AutoARIMA | 0.049824 |
| AutoETS | 0.049824 |
| MSTL | 0.050669 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.980 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.664 |
| Revenue per Share | 0.173 |
| Market Cap | 263,481,376 |
| Forward P/E | 4.30 |
| Beta | 1.57 |
| Profit Margins | -246.48% |
| Website | https://www.acimmune.com |
As of Aug. 22, 2026, 2:04 a.m. EDT: Speculators are positioning for a moderate upside move, evidenced by significant open interest in out-of-the-money calls at the $5.00 strike across multiple expirations, which represents a 72% distance from current prices. This bullish skew contrasts with relatively light put volume, suggesting traders are betting on a recovery driven by the amended collaboration deal and pipeline data rather than a defensive hedge against further decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19909501 |
| Address1 | Building B |
| Address2 | EPFL Innovation Park |
| All Time High | 19.97 |
| All Time Low | 1.43 |
| Ask | 2.9 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 231,060 |
| Average Daily Volume3 Month | 260,580 |
| Average Volume | 260,580 |
| Average Volume10Days | 231,060 |
| Beta | 1.571 |
| Bid | 1.6 |
| Bid Size | 2 |
| Book Value | 0.43966445 |
| City | Lausanne |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.65 |
| Current Ratio | 0.932 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.74 |
| Day Low | 2.65 |
| Debt To Equity | 11.664 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -42,479,000 |
| Ebitda Margins | -2.42612 |
| Enterprise To Ebitda | -4.525 |
| Enterprise To Revenue | 10.979 |
| Enterprise Value | 192,226,368 |
| Eps Current Year | -0.40967 |
| Eps Forward | 0.6165738 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 41 21 345 91 20 |
| Fifty Day Average | 2.458 |
| Fifty Day Average Change | 0.19200015 |
| Fifty Day Average Change Percent | 0.07811235 |
| Fifty Two Week Change Percent | 19.9095 |
| Fifty Two Week High | 4.0 |
| Fifty Two Week High Change | -1.3499999 |
| Fifty Two Week High Change Percent | -0.33749998 |
| Fifty Two Week Low | 2.04 |
| Fifty Two Week Low Change | 0.61000013 |
| Fifty Two Week Low Change Percent | 0.29901966 |
| Fifty Two Week Range | 2.04 - 4.0 |
| Financial Currency | CHF |
| First Trade Date Milliseconds | 1,474,637,400,000 |
| Float Shares | 39,185,148 |
| Forward Eps | 0.6165738 |
| Forward P E | 4.2979445 |
| Free Cashflow | -33,138,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 90 |
| Fullday Change | -0.0599999 |
| Fullday Change Percent | -2.21402 |
| Fullday Price | 2.65 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.62231 |
| Gross Profits | -28,405,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37903 |
| Held Percent Institutions | 0.24347 |
| Implied Shares Outstanding | 99,426,932 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. |
| Long Name | AC Immune SA |
| Market | us_market |
| Market Cap | 263,481,376 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22309440 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -43,156,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 269,446,985 |
| Number Of Analyst Opinions | 4 |
| Open | 2.73 |
| Operating Cashflow | -50,494,000 |
| Operating Margins | 0.078940004 |
| Payout Ratio | 0.0 |
| Phone | 41 21 345 91 21 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.65 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 2.71 |
| Price Eps Current Year | -6.4686213 |
| Price Hint | 4 |
| Price To Book | 6.027324 |
| Price To Sales Trailing12 Months | 15.04834 |
| Profit Margins | -2.46479 |
| Quick Ratio | 0.888 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -2.21402 |
| Regular Market Day High | 2.74 |
| Regular Market Day Low | 2.65 |
| Regular Market Day Range | 2.65 - 2.74 |
| Regular Market Open | 2.73 |
| Regular Market Previous Close | 2.71 |
| Regular Market Price | 2.65 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 105,642 |
| Return On Assets | -0.16036 |
| Return On Equity | -0.78528 |
| Revenue Growth | 10.572 |
| Revenue Per Share | 0.173 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 99,426,932 |
| Shares Percent Shares Out | 0.0343 |
| Shares Short | 3,405,907 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,395,949 |
| Short Name | AC Immune SA |
| Short Percent Of Float | 0.0733 |
| Short Ratio | 16.29 |
| Source Interval | 15 |
| Symbol | ACIU |
| Target High Price | 11.844805 |
| Target Low Price | 5.3441243 |
| Target Mean Price | 8.521253 |
| Target Median Price | 8.448042 |
| Total Cash | 75,357,000 |
| Total Cash Per Share | 0.758 |
| Total Debt | 4,102,000 |
| Total Revenue | 17,509,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.847775 |
| Two Hundred Day Average Change | -0.19777489 |
| Two Hundred Day Average Change Percent | -0.06944892 |
| Type Disp | Equity |
| Volume | 105,642 |
| Website | https://www.acimmune.com |
| Zip | 1,015 |